Table 5.

Characteristics of the included articles that used propensity score stratification as primary analyses (n=1)

Author and country	Setting and study period	Study population	Patient characteristics (range between NOACs)	Primary outcome definition	PS details	Sample size	Results/conclusion as reported in the article
Gorst-Rasmussen et al,41 Denmark	Danish National Prescription Registry, Danish National Patient Register, Danish Civil Registration System 1 February 2012–31 July 2014	NVAF patients who were new users of OAC (no OAC treatment in at least the last 2 years)	Standard dose: Age: 66.0±8.5–72.8±9.9 Male: 51.1%–63.5% CHA2DS2-VASc: 2.1–3.0 Comorbidity index: NR	Ischaemic stroke/systemic embolism/transient ischaemic attack, any bleeding and all-cause death. ICD-10 codes, whether primary and secondary codes were used is not described	Asymmetric trimming of the propensity score. Trimmed propensity score was used in 10 deciles as strata. Balanced if the absolute value of the STD was ≤10%.	Dabigatran: n=8908 Rivaroxaban: n=1405;	Rivaroxaban and dabigatran had similar stroke rates. Bleeding and mortality rates were higher in rivaroxaban vs dabigatran.

CHA2DS2-Vasc, Congestive heart failure, Hypertension, Age ≥75 years, Diabetes Mellitus, Prior Stroke or TIA or thromboembolism, Vascular disease, Age 65–74 years, Sex; NOACs, non-vitamin K antagonist oral anticoagulants; NVAF, non-valvular atrial fibrillation; OAC, oral anticoagulants.